

57. (amended) The method of claim 55 wherein the prokinetic agent is metoclopramide, domperidone, erythromycin or cisapride.


REMARKS

For the sole purpose of reducing initial filing fees, claims 8-12, 21-23, 26-28, 30-34, 36-41, 45-48, 50 and 52 have been cancelled without prejudice, and claims 4-7, 13-15, 20, 24, 25, 29, 43, 49, 51, 53-55, and 57 have been amended. No new matter has been added by virtue of the amendments.


An Information Disclosure Statement will be submitted under separate cover.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,



Peter F. Corless (Reg. 33,860)
EDWARDS & ANGELL, LLP
Dike, Bronstein, Roberts & Cushman IP Group
P.O. Box 9169
Boston, MA 02209
(617) 439-4444



COPY OF PAPERS
ORIGINALLY FILED

VERSION SHOWING MARKED CHANGES

4. (amended) The method of claim 1 or 2 [any one of claims 1 through 3] wherein the amount of the administered compound is sufficient to increase neuronal cyclic guanosine 3'-monophosphate (cGMP) levels as measured by a standard cGMP assay.
5. (amended) The method of claim 1 or 2 [any one of claims 1 through 4] wherein the gastrointestinal disorder is characterized by hypomotility or hypermotility in at least one of the small intestine, large intestine, colon, esophagus or stomach.
6. (amended) The method of claim 1 or 2 [any one of claims 1 through 5] wherein the gastrointestinal disorder is further characterized by at least one of nausea, vomiting, heartburn, postprandial discomfort, diarrhea, constipation, and indigestion.
7. (amended) The method of claim 1 or 2 [any one of claims 1 through 6] wherein the disorder is associated with at least one of diabetes, anorexia nervosa, bulimia, achlorhydria, achalasia, anal fissure, irritable bowel syndrome, intestinal pseudoobstruction, scleroderma and gastrointestinal damage.
13. (amended) The method of claim 1 or 2 [any one of claims 1 through 4] wherein the mammal is suffering from or susceptible to Crohn's disease or ulcerative colitis.
14. (amended) The method of claim 1 or 2 [any one of claims 1 through 14] wherein a PDE inhibitor compound is administered.
15. (amended) The method of claim 1 or 2 [any one of claims 1 through 14] wherein insulin, a biologically active variant of insulin, or a compound that boosts insulin effects or levels is administered.

20. (amended) The method of claim 17 [claims 17 or 19] wherein the inhibitor decreases activity of a type 5 PDE (PDE5).

24. (amended) The method of claim 18 [or 23] wherein the compound that can boost insulin effects or levels is administered in conjunction with a PDE inhibitor compound.

25. (amended) The method of any one of claims 1, 2, 17 or 18 [through 24] wherein at least one of the administered compounds is represented by anyone of Formulae I through XIII as those formulae are set forth above as well as pharmaceutically acceptable salts and solvates thereof.

29. (amended) The method of any one of claims 1, 2, 17 or 18 [through 28] wherein Viagra is administered to the mammal.

43. (amended) The method of claim 42 [any one of claims 35 through 42] wherein the mammal has been identified as suffering from diabetic gastropathy and selected for treatment for diabetic gastropathy.

49. (amended) The method of claim 44 [any one of claims 44 through 48] wherein insulin, a biologically active variant of insulin, or a compound that boosts insulin effects or levels is administered to the mammal.

51. (amended) The method of claim 44 [any one of claims 44 through 50] wherein the mammal has been identified as suffering from diabetes, anorexia nervosa, bulimia, achlorhydria, achalasia, anal fissure, irritable bowel syndrome, intestinal pseudoobstruction, scleroderma, gastrointestinal damage, Crohn's disease or ulcerative colitis, and the mammal has been selected for treatment for diabetes, anorexia nervosa, bulimia, achlorhydria, achalasia, anal

fissure, irritable bowel syndrome, intestinal pseudoobstruction, scleroderma, gastrointestinal damage, Crohn's disease or ulcerative colitis.

53. (amended) The method of claims 1 or 2 [any one of claims 52] wherein the mammal is a human patient.

54. (amended) The method of claims 1 or 2 [any one of claims 1 through 53] wherein the mammal has been subjected to or will be subjected to treatment with at least one prokinetic agent.

55. (amended) The method of claims 1 or 2 [any one of claims 1 through 54] wherein the method further comprises administering to the mammal a therapeutically effective amount of at least one prokinetic agent.

57. (amended) The method of claim [54 or] 55 wherein the prokinetic agent is metoclopramide, domperidone, erythromycin or cisapride.